Predicting Liver Cancer: A New AI Breakthrough from Medical IP

Medical IP, an AI-based digital twin solution company, recently received approval for its AI liver cancer prediction device, marking a significant milestone. Their software, DeepFore and DeepFore Recur, became the first AI medical devices globally approved to predict liver cancer onset and recurrence risk. Understanding liver cancer risks early can improve management and survival, making this innovation noteworthy.

The Challenge of Detecting Liver Cancer

The liver is often called a “silent organ” because symptoms arise late, making early detection hard. Despite ranked 7th in occurrence, liver cancer has the 2nd highest mortality rate in Korea, with over half of cases recurring within five years post-treatment. The clustering of complex organs like the liver and pancreas in the abdominal area makes AI analysis challenging. However, Medical IP overcame these hurdles with their innovative software.

DeepFore and DeepFore Recur: What They Do

• DeepFore: Analyzes CT images and electronic medical records (EMR) of chronic hepatitis B patients to predict their liver cancer development risk within the next eight years.
• DeepFore Recur: Focuses on postoperative patients, using imaging and EMR to calculate recurrence probabilities and providing this data to healthcare providers.

These programs evolved from the existing DeepCatch, advancing to integrate diverse medical data for improved liver cancer prediction.

Development and Support

DeepFore and DeepFore Recur are part of the South Korean government-backed “Dr. Answer 2.0” AI project, initiated in 2021. It involved major hospitals like:

• Seoul National University Hospital
• Samsung Medical Center
• Severance Hospital

The project received approximately $206 million, of which $2.06 million was government-funded.

Impact on Personalized Cancer Risk Management

Chronic hepatitis B patients are advised to undergo regular ultrasound and blood tests every six months. However, these methods are limited to assessing the current state, offering no prediction. DeepFore series addresses this gap, setting a precedent for predictive, personalized liver cancer risk management.

• Predictive Capability: Beyond diagnosis, these tools predict disease occurrence and recurrence.
• Custom Solutions: Offers personalized risk assessments for liver cancer.
• Industry First: First globally to receive medical device approval for AI-driven liver cancer prediction.

Future Plans

Medical IP aims to strengthen the institutional framework for the DeepFore series with evaluations like new medical technology assessments and expand into the preventive liver cancer market.

Conclusion

Medical IP’s innovation in AI medical diagnostics sets a new course for liver cancer risk management. The DeepFore series offers a proactive approach by predicting cancer risks, empowering healthcare providers and patients to manage liver cancer better. The future of personalized, preventative care looks promising with such advancements.